Indole and azaindole derivative having ampk-activating activity

a technology of ampk activation and azaindole, which is applied in the direction of drug compositions, extracellular fluid disorders, metabolic disorders, etc., can solve the problems of not disclosing the ampk activation effect, and achieves good metabolic stability, high oral absorption, and use as a medicine

Inactive Publication Date: 2018-05-24
SHIONOGI & CO LTD
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The compound exhibits excellent AMPK activating effects, providing a medicinal product for effectively managing type II diabetes, hyperglycemia, metabolic syndrome, obesity, and hypertension with improved metabolic stability and safety profiles.

Problems solved by technology

However, any of Patent Documents 9 to 22 does not disclose the AMPK activating effect.
However, any of Non-patent Documents 2 to 13 does not disclose the AMPK activating effect.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Indole and azaindole derivative having ampk-activating activity
  • Indole and azaindole derivative having ampk-activating activity
  • Indole and azaindole derivative having ampk-activating activity

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0436]

[0437]5-bromo-6-chloro-1H-indole 1 (2.00 g, 8.68 mmol) was dissolved in DMF (5 mL) and dichloromethane (5 mL), and POCl3 (5 mL) was added thereto, and the reaction mixture was stirred at room temperature for approximately an hour. Thereafter, the reaction mixture was treated with iced water, and then dichloromethane was removed under reduced pressure. The precipitated solid was filtered to obtain Compound 2 (2.10 g, 93.6%).

Compound 2;

Method B

[0438]LC / MS retention time=1.77 min.

[0439]MS (ESI) m / z=259.75 (M+H)+.

[0440]Compound 2 (1.00 g, 3.87 mmol) and hydroxyamine hydrochloride (296 mg, 4.26 mmol) were dissolved in pyridine (5 mL), and the mixture was stirred at room temperature for approximately an hour. Thereafter, acetic anhydride (804 μl, 8.51 mmol) was added thereto, and the reaction mixture was stirred with heating at 90° C. for approximately an hour. The mixture was cooled to room temperature, diluted with ethyl acetate, and washed with 2N aqueous solution of hydrochloric...

example 2

[0452]

[0453]To a solution of DMF (5 mL) and dichloromethane (5 mL) was added POCl3 (5 mL) at room temperature, and the mixture was stirred for 10 minutes. Thereafter, a suspension of 5-bromooxyindole 8 (2.55 g, 12 mmol) in dichloromethane (12.5 mL) / pyridine (2.5 mL) was added thereto, and the reaction mixture was stirred at room temperature for approximately 2 hours and then at 40° C. for approximately 4 hours. The reaction mixture was treated with iced water and concentrated under reduced pressure. The precipitated solid was filtered. The precipitated solid from the filtrate was filtered to obtain Compound 9 (819.5 mg, 26.4%).

Compound 9;

Method B

[0454]LC / MS retention time=1.80 min.

[0455]MS (ESI) m / z=259.75 (M+H)+.

[0456]To Compound 9 (100 mg, 0.387 mmol) were added pyridine (1 mL) and hydroxylamine hydrochloride (29.6 mg, 0.426 mmol), and the mixture was stirred at room temperature for approximately an hour. Thereafter, acetic anhydride (160 μL, 1.7 mmol) was added thereto, and the r...

example 3

[0462]

[0463]To Compound 12 (5.47 g, 30 mmol) were added nitric acid (30 mL) and concentrated sulfuric acid (24 mL) at room temperature, and the reaction mixture was warmed up to 100° C. and stirred with heating for approximately 8 hours. The reaction mixture was added to iced water, the resulting mixture was stirred. The precipitated solid was filtered to obtain Compound 13 (6.82 g, 64.7%).

Compound 13;

Method B

[0464]LC / MS retention time=2.03 min.

[0465]Ethyl 2-cyanoacetate (2.98 g, 26.4 mmol) was diluted with t-BuOH (60 mL), and t-BuOK (2.96 g, 26.4 mmol) and Compound 13 (3.00 g, 13.2 mmol) were added thereto under ice-cooling, and the reaction mixture was warmed up to room temperature and then stirred. After being stirred for approximately 40 minutes, the reaction mixture was treated with 2N aqueous solution of hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with water and brine, dried over magnesium sulfate, and concentrated under reduced pressure. T...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A compound is represented by formula:or its pharmaceutically acceptable salt, wherein Y is substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, or heterocyclyl; T is —CR7═; U is —CR8═ or —N═; R2 is hydrogen, halogen, cyano, nitro, carboxy, substituted or unsubstituted alkyl, alkenyl, acyl, carbamoyl, alkylthio, alkylsulfinyl, alkylsulfonyl, or alkyloxycarbonyl; R3 is halogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocyclyl; R4 and R8 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, or heterocyclyl; and R7 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocyclyl, alkyloxy, aryloxy, heteroaryloxy, cycloalkyloxy, cycloalkenyloxy, heterocyclyloxy, alkylthio, arylthio, heteroarylthio, cycloalkylthio, cycloalkenylthio, heterocyclylthio, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, cycloalkylsulfonyl, cycloalkenylsulfonyl, heterocyclylsulfonyl, acyl, carbamoyl, sulfamoyl, or amino.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]The present application is a divisional of U.S. application Ser. No. 14 / 413,337, filed Jan. 7, 2015, the entire contents of which are incorporated herein by reference. U.S. application Ser. No. 14 / 413,337 is a National Stage of International Application No. PCT / JP2014 / 054699, filed Feb. 26, 2014, which is based upon and claims the benefit of priority to Japanese Applications No. 2013-036578, filed Feb. 27, 2013 and No. 2013-151281, filed Jul. 22, 2013. The present application claims the benefit of priority to Japanese Applications No. 2013-036578 and No. 2013-151281, U.S. application Ser. No. 14 / 413,337, and International Application No. PCT / JP2014 / 054699.FIELD OF THE INVENTION[0002]The present invention relates to a compound which has an activating effect on adenosine monophosphate-activated protein kinase (hereinafter referred to as AMPK) and is useful as a medicine.BACKGROUND ART[0003]AMPK is a serine-threonine kinase, which is activat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(United States)
IPC IPC(8): C07D209/34A61K31/5377C07D405/12C07D471/04C07D493/04A61K31/4045C07D519/00C07H17/02C07D403/12C07D413/12C07D209/42
CPCC07D209/34A61K31/5377C07D405/12C07D471/04C07D493/04A61K31/4045C07D519/00C07H17/02C07D403/12C07D413/12C07D209/42A61P1/16A61P3/00A61P3/04A61P3/06A61P3/10A61P5/50A61P7/00A61P9/12A61P43/00
InventorTAMURA, YUUSUKEKOJIMA, EIICHIHINATA, YU
OwnerSHIONOGI & CO LTD